# US 2024/0199757 A1 · Cd73 (nt5e) targeting polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199757 A1
- Document ID: US20240199757A1
- Status: Published application
- Kind: A1
- Application number: 18/590,875
- Filed: 2024-02-28
- Published: 2024-06-20
- Earliest claimed: 2022-06-30
- Assignees: The University of Chicago
- Applicants: The University of Chicago
- Inventors: Anthony KOSSIAKOFF; Carla E. MEINTS; Somnath MUKHERJEE
- Web page: https://patentgrep.com/patent/US20240199757A1

## CPC

- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61K 51/1021: {against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons}
- A61K 51/1027: {against receptors, cell-surface antigens or cell-surface determinants}
- A61K 51/1093: {conjugates with carriers being antibodies}
- A61P 35/00: Antineoplastic agents
- G01N 33/54306: {Solid-phase reaction mechanisms}
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- G01N 33/60: involving radioactive labelled substances
- A61K 2039/505: {comprising antibodies}
- A61K 2121/00: Preparations for use in therapy
- A61K 2123/00: Preparations for testing in vivo
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Aspects of the present disclosure are directed to NT5E (CD73)-targeting polypeptides, including antibodies, antibody-drug conjugates, antibody fragments, antibody-like molecules, and chimeric receptors. Also disclosed herein are nucleic acids encoding for such NT5E-targeting polypeptides and cells comprising such nucleic acids. Described are methods for treatment of cancer using NT5E-targeting polypeptides.

## Claims

### Claim 1

An antibody or antigen binding fragment comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a HCDR1, HCDR2, and HCDR3 from a heavy chain variable region of Table 1 and wherein the light chain variable region comprises a LCDR1, LCDR2, and LCDR3 from a light chain variable region of Table 1.

### Claim 2

An antibody or antigen binding fragment comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a HCDR1, HCDR2, and HCDR3 having at least 80% sequence identity with a HCDR1, HCDR2, and HCDR3 from a heavy chain variable region of Table 1 and wherein the light chain variable region comprises a LCDR1, LCDR2, and LCDR3 having at least 80% sequence identity with a LCDR1, LCDR2, and LCDR3 from a light chain variable region of Table 1.

### Claim 3 (depends on 1, 2)

The antibody of claim 1 or 2, wherein the heavy chain variable region and light chain variable region of Table 1 are from the same antibody clone of Table 1.

### Claim 4

An antibody or antigen binding fragment comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a HCDR1, HCDR2, and HCDR3 comprising the amino acid sequence of SEQ ID NOs:1-3, respectively, and wherein the light chain variable region comprises a LCDR3 comprising the amino acid sequence of SEQ ID NO:6.

### Claim 5

An antibody or antigen binding fragment comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a HCDR1, HCDR2, and HCDR3 comprising the amino acid sequence of SEQ ID NOs:1-3, respectively, and wherein the light chain variable region comprises a LCDR1, LCDR2, and LCDR3 comprising the amino acid sequence of SEQ ID NOs:4-6, respectively.

### Claim 6

An antibody or antigen binding fragment comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a HCDR1, HCDR2, and HCDR3 having at least 80% sequence identity to SEQ ID NOs:1-3, respectively, and wherein the light chain variable region comprises a LCDR1, LCDR2, and LCDR3 having at least 80% sequence identity to SEQ ID NOs:4-6, respectively.

### Claim 7 (depends on 4, 5, 6)

The antibody or antigen binding fragment of any of claims 4-6, wherein the heavy chain variable region comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO:7 and/or the light chain variable region comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO:8.

### Claim 8 (depends on 4, 5, 6, 7)

The antibody or antigen binding fragment of any of claims 4-7, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:7 and/or the light chain variable region comprises the amino acid sequence of SEQ ID NO:8.

### Claim 9 (depends on 4, 5, 6, 7, 8)

The antibody or antigen binding fragment of any one of claims 4-8, wherein the antibody or antigen binding fragment comprises an amino acid sequence with at least 70% sequence identity to one of SEQ ID NOs:1-10 and/or an amino acid sequence with 1 substitution relative to SEQ ID NOs:1-10.

### Claim 10 (depends on 4, 5, 6, 7, 8, 9)

The antibody of any one of claims 4-9, wherein the antibody comprises a heavy chain and a light chain and wherein the heavy chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO:9 and the light chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO:10.

### Claim 11

An antibody or antigen binding fragment comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a HCDR1, HCDR2, and HCDR3 comprising the amino acid sequence of SEQ ID NOs:11-13, respectively, and wherein the light chain variable region comprises a LCDR3 comprising the amino acid sequence of SEQ ID NO:16.

### Claim 12

An antibody or antigen binding fragment comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a HCDR1, HCDR2, and HCDR3 comprising the amino acid sequence of SEQ ID NOs:11-13, respectively, and wherein the light chain variable region comprises a LCDR1, LCDR2, and LCDR3 comprising the amino acid sequence of SEQ ID NOs:14-16, respectively.

### Claim 13

An antibody or antigen binding fragment comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a HCDR1, HCDR2, and HCDR3 having at least 80% sequence identity to SEQ ID NOs:11-13, respectively, and wherein the light chain variable region comprises a LCDR1, LCDR2, and LCDR3 having at least 80% sequence identity to SEQ ID NOs:14-16, respectively.

### Claim 14 (depends on 11, 12, 13)

The antibody or antigen binding fragment of any of claims 11-13, wherein the heavy chain variable region comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO:17 and/or the light chain variable region comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO:18.

### Claim 15 (depends on 11, 12, 13, 14)

The antibody or antigen binding fragment of any of claims 11-14, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:17 and/or the light chain variable region comprises the amino acid sequence of SEQ ID NO:18.

### Claim 16 (depends on 11, 12, 13, 14, 15)

The antibody or antigen binding fragment of any one of claims 11-15, wherein the antibody or antigen binding fragment comprises an amino acid sequence with at least 70% sequence identity to one of SEQ ID NOs:11-20 and/or an amino acid sequence with 1 substitution relative to SEQ ID NOs:11-20.

### Claim 17 (depends on 11, 12, 13, 14, 15, 16)

The antibody of any one of claims 11-16, wherein the antibody comprises a heavy chain and a light chain and wherein the heavy chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO:19 and the light chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO:20.

### Claim 18

An antibody or antigen binding fragment comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a HCDR1, HCDR2, and HCDR3 comprising the amino acid sequence of SEQ ID NOs:21-23, respectively, and wherein the light chain variable region comprises a LCDR3 comprising the amino acid sequence of SEQ ID NO:26.

### Claim 19

An antibody or antigen binding fragment comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a HCDR1, HCDR2, and HCDR3 comprising the amino acid sequence of SEQ ID NOs:21-23, respectively, and wherein the light chain variable region comprises a LCDR1, LCDR2, and LCDR3 comprising the amino acid sequence of SEQ ID NOs:24-26, respectively.

### Claim 20

An antibody or antigen binding fragment comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a HCDR1, HCDR2, and HCDR3 having at least 80% sequence identity to SEQ ID NOs:21-23, respectively, and wherein the light chain variable region comprises a LCDR1, LCDR2, and LCDR3 having at least 80% sequence identity to SEQ ID NOs:24-26, respectively.

### Claim 21 (depends on 18, 19, 20)

The antibody or antigen binding fragment of any of claims 18-20, wherein the heavy chain variable region comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO:27 and/or the light chain variable region comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO:28.

### Claim 22 (depends on 18, 19, 20, 21)

The antibody or antigen binding fragment of any of claims 18-21, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:27 and/or the light chain variable region comprises the amino acid sequence of SEQ ID NO:28.

### Claim 23 (depends on 18, 19, 20, 21, 22)

The antibody or antigen binding fragment of any one of claims 18-22, wherein the antibody or antigen binding fragment comprises an amino acid sequence with at least 70% sequence identity to one of SEQ ID NOs:21-30 and/or an amino acid sequence with 1 substitution relative to SEQ ID NOs:21-30.

### Claim 24 (depends on 18, 19, 20, 21, 22, 23)

The antibody of any one of claims 18-23, wherein the antibody comprises a heavy chain and a light chain and wherein the heavy chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO:29 and the light chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO:30.

### Claim 25

An antibody or antigen binding fragment comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a HCDR1, HCDR2, and HCDR3 comprising the amino acid sequence of SEQ ID NOs:31-33, respectively, and wherein the light chain variable region comprises a LCDR3 comprising the amino acid sequence of SEQ ID NO:36.

### Claim 26

An antibody or antigen binding fragment comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a HCDR1, HCDR2, and HCDR3 comprising the amino acid sequence of SEQ ID NOs:31-33, respectively, and wherein the light chain variable region comprises a LCDR1, LCDR2, and LCDR3 comprising the amino acid sequence of SEQ ID NOs:34-36, respectively.

### Claim 27

An antibody or antigen binding fragment comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a HCDR1, HCDR2, and HCDR3 having at least 80% sequence identity to SEQ ID NOs:31-33, respectively, and wherein the light chain variable region comprises a LCDR1, LCDR2, and LCDR3 having at least 80% sequence identity to SEQ ID NOs:34-36, respectively.

### Claim 28 (depends on 25, 26, 27)

The antibody or antigen binding fragment of any of claims 25-27, wherein the heavy chain variable region comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO:37 and/or the light chain variable region comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO:38.

### Claim 29 (depends on 25, 26, 27, 28)

The antibody or antigen binding fragment of any of claims 25-28, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:37 and/or the light chain variable region comprises the amino acid sequence of SEQ ID NO:38.

### Claim 30 (depends on 25, 26, 27, 28, 29)

The antibody or antigen binding fragment of any one of claims 25-29, wherein the antibody or antigen binding fragment comprises an amino acid sequence with at least 70% sequence identity to one of SEQ ID NOs:31-40 and/or an amino acid sequence with 1 substitution relative to SEQ ID NOs:31-40.

### Claim 31 (depends on 25, 26, 27, 28, 29, 30)

The antibody of any one of claims 25-30, wherein the antibody comprises a heavy chain and a light chain and wherein the heavy chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO:39 and the light chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO:40.

### Claim 32

An antibody or antigen binding fragment comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a HCDR1, HCDR2, and HCDR3 comprising the amino acid sequence of SEQ ID NOs:41-43, respectively, and wherein the light chain variable region comprises a LCDR3 comprising the amino acid sequence of SEQ ID NO:46.

### Claim 33

An antibody or antigen binding fragment comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a HCDR1, HCDR2, and HCDR3 comprising the amino acid sequence of SEQ ID NOs:41-43, respectively, and wherein the light chain variable region comprises a LCDR1, LCDR2, and LCDR3 comprising the amino acid sequence of SEQ ID NOs:44-46, respectively.

### Claim 34

An antibody or antigen binding fragment comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a HCDR1, HCDR2, and HCDR3 having at least 80% sequence identity to SEQ ID NOs:41-43, respectively, and wherein the light chain variable region comprises a LCDR1, LCDR2, and LCDR3 having at least 80% sequence identity to SEQ ID NOs:44-46, respectively.

### Claim 35 (depends on 32, 33, 34)

The antibody or antigen binding fragment of any of claims 32-34, wherein the heavy chain variable region comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO:47 and/or the light chain variable region comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO:48.

### Claim 36 (depends on 32, 33, 34, 35)

The antibody or antigen binding fragment of any of claims 32-35, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:47 and/or the light chain variable region comprises the amino acid sequence of SEQ ID NO:48.

### Claim 37 (depends on 32, 33, 34, 35, 36)

The antibody or antigen binding fragment of any one of claims 32-36, wherein the antibody or antigen binding fragment comprises an amino acid sequence with at least 70% sequence identity to one of SEQ ID NOs:41-50 and/or an amino acid sequence with 1 substitution relative to SEQ ID NOs:41-50.

### Claim 38 (depends on 32, 33, 34, 35, 36, 37)

The antibody of any one of claims 32-37, wherein the antibody comprises a heavy chain and a light chain and wherein the heavy chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO:49 and the light chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO:50.

### Claim 39

An antibody or antigen binding fragment comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a HCDR1, HCDR2, and HCDR3 comprising the amino acid sequence of SEQ ID NOs:51-53, respectively, and wherein the light chain variable region comprises a LCDR3 comprising the amino acid sequence of SEQ ID NO:56.

### Claim 40

An antibody or antigen binding fragment comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a HCDR1, HCDR2, and HCDR3 comprising the amino acid sequence of SEQ ID NOs:51-53, respectively, and wherein the light chain variable region comprises a LCDR1, LCDR2, and LCDR3 comprising the amino acid sequence of SEQ ID NOs:54-56, respectively.

### Claim 41

An antibody or antigen binding fragment comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a HCDR1, HCDR2, and HCDR3 having at least 80% sequence identity to SEQ ID NOs:51-53, respectively, and wherein the light chain variable region comprises a LCDR1, LCDR2, and LCDR3 having at least 80% sequence identity to SEQ ID NOs:54-56, respectively.

### Claim 42 (depends on 39, 40, 41)

The antibody or antigen binding fragment of any of claims 39-41, wherein the heavy chain variable region comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO:57 and/or the light chain variable region comprises an amino acid sequence with at least 80% sequence identity to SEQ ID NO:58.

### Claim 43 (depends on 39, 40, 41, 42)

The antibody or antigen binding fragment of any of claims 39-42, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:57 and/or the light chain variable region comprises the amino acid sequence of SEQ ID NO:58.

### Claim 44 (depends on 39, 40, 41, 42, 43)

The antibody or antigen binding fragment of any one of claims 39-43, wherein the antibody or antigen binding fragment comprises an amino acid sequence with at least 70% sequence identity to one of SEQ ID NOs:51-60 and/or an amino acid sequence with 1 substitution relative to SEQ ID NOs:51-60.

### Claim 45 (depends on 39, 40, 41, 42, 43, 44)

The antibody of any one of claims 39-44, wherein the antibody comprises a heavy chain and a light chain and wherein the heavy chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO:59 and the light chain comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO:60.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The antibody of any one of claims 1-45, wherein the antibody is human, chimeric, or humanized.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The antibody or antigen-binding fragment of any one of claims 1-46, wherein the antibody or antigen binding fragment binds NT5E with a KD of about 10−6 M to about 10−12 M.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The antibody or antigen-binding fragment of any one of claims 1-47, wherein the antibody or antigen binding fragment binds NT5E with a KD of less than 20 nM.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The antibody or antigen-binding fragment of any one of claims 1-48, wherein the antibody or antigen binding fragment binds NT5E with a KD of less than 1 nM.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The antibody or antigen-binding fragment of any one of claims 1-49, wherein the antibody or antigen binding fragment binds NT5E with a higher affinity in the presence of ATP than in the absence of ATP.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The antibody or antigen-binding fragment of any one of claims 1-50, wherein the antibody or antigen binding fragment binds NT5E with at least a 3-fold higher affinity in the presence of ATP than in the absence of ATP.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The antibody or antigen-binding fragment of any one of claims 1-51, wherein the antibody or antigen binding fragment binds NT5E with at least a 5-fold higher affinity in the presence of ATP than in the absence of ATP.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The antibody or antigen-binding fragment of any one of claims 1-52, wherein the antibody or antigen binding fragment binds NT5E with at least a 10-fold higher affinity in the presence of ATP than in the absence of ATP.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The antibody or antigen binding fragment of any one of claims 1-53, wherein the antibody is a human antibody, humanized antibody, recombinant antibody, chimeric antibody, an antibody derivative, a veneered antibody, a diabody, a monoclonal antibody, a single domain antibody, or a single chain antibody.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The antigen binding fragment of any one of claims 1-54, wherein the antigen binding fragment is a single chain variable fragment (scFv), F(ab′)2, Fab′, Fab, Fv, or rIgG.

### Claim 56 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

A polypeptide comprising the antigen binding fragment of any one of claims 1-55.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

A composition comprising the antibody or antigen binding fragment of any one of claims 1-55.

### Claim 58 (depends on 57)

The composition of claim 57, wherein the composition comprises a pharmaceutical excipient.

### Claim 59 (depends on 57, 58)

The composition of claim 57 or 58, wherein the composition comprises at least two antibodies or antigen binding fragments.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

One or more nucleic acids encoding the antibody or antigen binding fragment of any one of claims 1-55 or the polypeptide of claim 56.

### Claim 61

A nucleic acid encoding a antibody heavy chain variable region, wherein the nucleic acid has at least 70% sequence identity to one of SEQ ID NOs:71-76.

### Claim 62 (depends on 61)

The nucleic acid of claim 61, wherein the nucleic acid has at least 90% sequence identity to one of SEQ ID NOs:71-76.

### Claim 63 (depends on 61)

The nucleic acid of claim 61, wherein the nucleic acid comprises one of SEQ ID NOs: 71-76.

### Claim 64

A nucleic acid encoding an antibody light chain variable region, wherein the nucleic acid has at least 70% sequence identity to one of SEQ ID NOs:78-83.

### Claim 65 (depends on 64)

The nucleic acid of claim 64, wherein the nucleic acid has at least 90% sequence identity to one of SEQ ID NOs:78-83.

### Claim 66 (depends on 64)

The nucleic acid of claim 64, wherein the nucleic acid comprises one of SEQ ID NOs:78-83.

### Claim 67 (depends on 61, 62, 63, 64, 65, 66)

A vector comprising the nucleic acid of any one of claims 61-66.

### Claim 68 (depends on 61, 62, 63, 64, 65, 66, 67)

A host cell comprising the nucleic acid of any one of claims 61-66 or the vector of claim 67.

### Claim 69 (depends on 68)

The host cell of claim 68, wherein the host cell is an immune cell.

### Claim 70 (depends on 69)

The host cell of claim 69, wherein the host cell is a B cell.

### Claim 71 (depends on 69)

The host cell of claim 69, wherein the host cell is an NK cell.

### Claim 72 (depends on 69)

The host cell of claim 69, wherein the host cell is a T cell.

### Claim 73 (depends on 61, 62, 63, 64, 65, 66, 67)

A method of a making a cell comprising transferring the nucleic acid(s) of any one of claims 61-66 or the vector of claim 67 into a cell.

### Claim 74 (depends on 73)

The method of claim 73, wherein the method further comprises culturing the cell under conditions that allow for expression of a polypeptide from the nucleic acid.

### Claim 75 (depends on 74)

The method of claim 74, wherein the method further comprising isolating the expressed polypeptide.

### Claim 76 (depends on 73, 74, 75)

The method of any one of claims 73-75, wherein the cell is immune cell.

### Claim 77 (depends on 76)

The method cell of claim 76, wherein the cell is a B cell.

### Claim 78 (depends on 76)

The method cell of claim 76, wherein the cell is an NK cell.

### Claim 79 (depends on 76)

The method cell of claim 76, wherein the cell is a T cell.

### Claim 80 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 68, 69, 70, 71, 72)

A method for treating or preventing cancer in a subject, the method comprising administering to the subject the antibody or antigen binding fragment of any one of claims 1-55, the polypeptide of claim 56, or the host cell of any of claims 68-72.

### Claim 81 (depends on 80)

The method of claim 80, wherein the subject is a human subject.

### Claim 82 (depends on 80, 81)

The method of claim 80 or 81, wherein the subject has one or more symptoms of cancer.

### Claim 83 (depends on 80, 81)

The method of claim 80 or 81, wherein the subject does not have any symptoms of cancer.

### Claim 84 (depends on 80, 81, 82, 83)

The method of any one of claims 80-83, wherein the subject has been diagnosed with cancer.

### Claim 85 (depends on 80, 81, 82, 83)

The method of any one of claims 80-83, wherein the subject has not been diagnosed with cancer.

### Claim 86 (depends on 80, 81, 82, 83, 84, 85)

The method of any one of claims 80-85, wherein the subject has been previously treated for cancer.

### Claim 87 (depends on 80, 81, 82, 83, 84, 85, 86)

The method of any one of claims 80-86, wherein the subject is administered an additional therapy.

### Claim 88 (depends on 87)

The method of claim 87, wherein the additional therapy comprises radiotherapy, chemotherapy, or immunotherapy.

### Claim 89 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

A method for evaluating a sample from a subject, the method comprising contacting a biological sample from the subject, or extract thereof, with at least one antibody, antigen binding fragment, or polypeptide of any one of claims 1-56.

### Claim 90 (depends on 89)

The method of claim 89, wherein the at least one antibody, antigen binding fragment, or polypeptide is operatively linked to a detectable label.

### Claim 91 (depends on 89, 90)

The method of claim 89 or 90, wherein the method further comprises incubating the antibody, antigen binding fragment, or polypeptide under conditions that allow for the binding of the antibody, antigen binding fragment, or polypeptide to antigens in the biological sample or extract thereof.

### Claim 92 (depends on 89, 90, 91)

The method of any one of claims 89-91, wherein the method further comprises detecting the binding of an antigen to the antibody, antigen binding fragment, or polypeptide.

### Claim 93 (depends on 89, 90, 91, 92)

The method of any one of claims 89-92, wherein the method further comprises contacting the biological sample with at least one capture antibody, antigen, or polypeptide.

### Claim 94 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 93)

The method of claim 93, wherein the at least one capture antibody, antigen binding fragment, or polypeptide comprises at least one antibody of claims 1-55.

### Claim 95 (depends on 93, 94)

The method of claim 93 or 94, wherein the capture antibody is linked to a solid support.

### Claim 96 (depends on 89, 90, 91, 92, 93, 94, 95)

The method of any one of claims 89-95, wherein the biological sample comprises a tissue sample or a blood sample.

### Claim 97

A method for treating a subject for cancer, the method comprising administering to the subject an effective amount of an antibody comprising:
a heavy chain variable region comprising:
a HCDR1 comprising the amino acid sequence of SEQ ID NO:1;
a HCDR2 comprising the amino acid sequence of SEQ ID NO:2; and
a HCDR3 comprising the amino acid sequence of SEQ ID NO:3; and
a light chain variable region comprising:
a LCDR1 comprising the amino acid sequence of SEQ ID NO:4;
a LCDR2 comprising the amino acid sequence of SEQ ID NO:5; and
a LCDR3 comprising the amino acid sequence of SEQ ID NO:6.

### Claim 98

A method for treating a subject for cancer, the method comprising administering to the subject an effective amount of an antibody comprising:
a heavy chain variable region comprising:
a HCDR1 comprising the amino acid sequence of SEQ ID NO:11;
a HCDR2 comprising the amino acid sequence of SEQ ID NO:12; and
a HCDR3 comprising the amino acid sequence of SEQ ID NO:13; and
a light chain variable region comprising:
a LCDR1 comprising the amino acid sequence of SEQ ID NO:14;
a LCDR2 comprising the amino acid sequence of SEQ ID NO:15; and
a LCDR3 comprising the amino acid sequence of SEQ ID NO:16.

### Claim 99

A method for treating a subject for cancer, the method comprising administering to the subject an effective amount of an antibody comprising:
a heavy chain variable region comprising:
a HCDR1 comprising the amino acid sequence of SEQ ID NO:21;
a HCDR2 comprising the amino acid sequence of SEQ ID NO:22; and
a HCDR3 comprising the amino acid sequence of SEQ ID NO:23; and
a light chain variable region comprising:
a LCDR1 comprising the amino acid sequence of SEQ ID NO:24;
a LCDR2 comprising the amino acid sequence of SEQ ID NO:25; and
a LCDR3 comprising the amino acid sequence of SEQ ID NO:26.

### Claim 100

A method for treating a subject for cancer, the method comprising administering to the subject an effective amount of an antibody comprising:
a heavy chain variable region comprising:
a HCDR1 comprising the amino acid sequence of SEQ ID NO:31;
a HCDR2 comprising the amino acid sequence of SEQ ID NO:32; and
a HCDR3 comprising the amino acid sequence of SEQ ID NO:33; and
a light chain variable region comprising:
a LCDR1 comprising the amino acid sequence of SEQ ID NO:34;
a LCDR2 comprising the amino acid sequence of SEQ ID NO:35; and
a LCDR3 comprising the amino acid sequence of SEQ ID NO:36.

### Claim 101

A method for treating a subject for cancer, the method comprising administering to the subject an effective amount of an antibody comprising:
a heavy chain variable region comprising:
a HCDR1 comprising the amino acid sequence of SEQ ID NO:41;
a HCDR2 comprising the amino acid sequence of SEQ ID NO:42; and
a HCDR3 comprising the amino acid sequence of SEQ ID NO:43; and
a light chain variable region comprising:
a LCDR1 comprising the amino acid sequence of SEQ ID NO:44;
a LCDR2 comprising the amino acid sequence of SEQ ID NO:45; and
a LCDR3 comprising the amino acid sequence of SEQ ID NO:46.

### Claim 102

A method for treating a subject for cancer, the method comprising administering to the subject an effective amount of an antibody comprising:
a heavy chain variable region comprising:
a HCDR1 comprising the amino acid sequence of SEQ ID NO:51;
a HCDR2 comprising the amino acid sequence of SEQ ID NO:52; and
a HCDR3 comprising the amino acid sequence of SEQ ID NO:53; and
a light chain variable region comprising:
a LCDR1 comprising the amino acid sequence of SEQ ID NO:54;
a LCDR2 comprising the amino acid sequence of SEQ ID NO:55; and
a LCDR3 comprising the amino acid sequence of SEQ ID NO:56.
